17-116 - Nivolumab and Ipilimumab in Treating Patients With Rare TumorsStatus: open
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (S1609)
Treatment for Rare Tumors
I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria.
After completion of study treatment, patients are followed up for 10 years from registration.
SponsorsThis trial is sponsored by SWOG.
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Professor of Interdisciplinary Clinical Oncology
- Daniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Thomas W. Butler, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Oncology
- Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology